Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

Br J Cancer · 2010 · PMC2938245 · PMID 20683448

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Crucially, dual inhibition of EGFR and mTOR pathways by erlotinib and RAD001 combination therapy showed a synergistic and highly significant antitumour effect that could be explained on the molecular level by synergistic regulation of both pathways (see Figure 3C ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.